A comparative profitability analysis of transcatheter versus surgical aortic valve replacement in a high-volume French hospital

François Huchet (), Jacques Chan-Peng (), Fanny d’Acremont (), Patrice Guerin (), Gael Grimandi (), Jean-Christian Roussel (), Julien Plessis (), Vincent Letocart (), Thomas Senage () and Thibaut Manigold ()
Additional contact information
François Huchet: Unité d’Hémodynamique et Cardiologie Interventionnelle, CHU de Nantes
Jacques Chan-Peng: Unité d’Hémodynamique et Cardiologie Interventionnelle, CHU de Nantes
Fanny d’Acremont: Pharmacie Centrale, Hôpital Saint-Jacques, CHU de Nantes
Patrice Guerin: Unité d’Hémodynamique et Cardiologie Interventionnelle, CHU de Nantes
Gael Grimandi: Pharmacie Centrale, Hôpital Saint-Jacques, CHU de Nantes
Jean-Christian Roussel: Service de chirurgie cardio-thoracique, Hôpital Nord Laennec, CHU de Nantes
Julien Plessis: Unité d’Hémodynamique et Cardiologie Interventionnelle, CHU de Nantes
Vincent Letocart: Unité d’Hémodynamique et Cardiologie Interventionnelle, CHU de Nantes
Thomas Senage: Service de chirurgie cardio-thoracique, Hôpital Nord Laennec, CHU de Nantes
Thibaut Manigold: Unité d’Hémodynamique et Cardiologie Interventionnelle, CHU de Nantes

Health Economics Review, 2019, vol. 9, issue 1, 1-7

Abstract: Abstract Background Current scientific guidelines have extended the indication for transcatheter aortic valve replacement (TAVR) to patients who present an intermediate risk for surgery and have been so far considered for conventional surgery. We previously demonstrated that the TAVR procedure generated profits despite elevated costs, but comparison with surgery has not been performed. The objective of this study was to assess the profitability of the TAVR procedure compared with conventional surgery in a high-volume French hospital. Consecutive patients eligible for transfemoral TAVR or surgical aortic valve replacement (SAVR) were included retrospectively in this single-centre study between September 2014 and December 2015. The primary endpoint was the profitability of each procedure (defined as the ratio between the profit and total revenues), calculated for each patient. Secondary composite endpoints included major adverse events in the 30 days following procedure and breakdown of costs. Results Two hundred and thirty-eight patients were included in the TAVR group and 341 in the SAVR group. TAVR patients presented higher operative risk scores and more comorbidities. Compared with SAVR, TAVR was associated with higher profits (€2732 ± 1768 per patient vs. €2177 ± 2437 per patient, P

Keywords: Economical/cost-effectiveness; Aortic valve disease; percutaneous intervention; Cardiovascular diseases (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-019-0223-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:9:y:2019:i:1:d:10.1186_s13561-019-0223-0

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-019-0223-0

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().